Latest Trials
Latest News
FAQ
Pharmaceutical Companies
Pharma Details
Mark Stegall
🇺🇸
United States
Country
🇺🇸
United States
Ownership
-
Employees
-
Market Cap
-
Website
Clinical Trials
Related News
Janssen Ad26.CoV2.S Vaccine Booster in Kidney Transplant Recipients
Phase 3
Active, not recruiting
Conditions
Kidney Transplant Recipient
Interventions
Biological: Janssen Ad26.CoV2.S Vaccine
Other: Reduction in Immunosuppression Medication
Other: Maintenance in Immunosuppression Medication
Subscribe
First Posted Date
2022-02-02
Last Posted Date
2024-07-12
Lead Sponsor
Mark Stegall
Target Recruit Count
1200
Registration Number
NCT05220397
Locations
🇺🇸
Mayo Clinic, Rochester, Minnesota, United States
Subscribe
Impact of Proteasome Inhibition on Anti-Donor HLA Antibody Production After Kidney Transplantation
Phase 2
Terminated
Conditions
Disorder of Transplanted Kidney
Interventions
Drug: Bortezomib
Subscribe
First Posted Date
2011-05-06
Last Posted Date
2015-10-28
Lead Sponsor
Mark Stegall
Target Recruit Count
4
Registration Number
NCT01349595
Locations
🇺🇸
Mayo Clinic, Rochester, Minnesota, United States
Subscribe
Dosing Regimen of Eculizumab Added to Conventional Treatment in Positive Cross Match Living Donor Kidney Transplant
Phase 1
Completed
Conditions
Kidney Transplant
Interventions
Drug: Eculizumab
Subscribe
First Posted Date
2008-05-02
Last Posted Date
2018-06-26
Lead Sponsor
Mark Stegall
Target Recruit Count
31
Registration Number
NCT00670774
Locations
🇺🇸
Mayo Clinic, Rochester, Minnesota, United States
Subscribe
Prev
1
Next
© Copyright 2024. All Rights Reserved by MedPath
Home
Terms & Conditions
Privacy Policy